New Milestone for Cancer Diagnosis in France as Ibex Medical Analytics Deploys AI-Based Pathology Technology at Medipath | 2020-07-21 | Press Releases


Ibex Galen ™ Prostate Solution is now used in routine clinical practice at From France the largest network of pathology laboratories, helping pathologists improve diagnostic accuracy TEL AVIV, Israel, and FREJUS, France, July 21, 2020 / PRNewswire / – Ibex medical analysis, a pioneer in artificial intelligence (AI) -based cancer diagnostics, and Medipath, the largest network of private pathology laboratories in France, today announced the very first deployment of an AI-based solution for the detection of cancer in pathology in France.

France, as in most European countries, is facing an increasing prevalence of cancer, resulting in an increased demand for diagnostic tests. This coincides with a worldwide decline in the number of pathologists, the experts needed to diagnose the disease, resulting in an increased workload. For many laboratories, the fundamentals of cancer diagnosis have remained unchanged for decades, with pathologists examining biopsies under a microscope. The process is manual and therefore subject to human error. Ibex now offers a field-proven, clinical-grade artificial intelligence-based solution that helps pathologists meet these challenges.

Medipath, which provides pathology services to more than 170 hospitals and clinics across France, completed the deployment of Prostate galène de bouquetin as part of normal clinical practice. With Ibex’s CE marked solution, a highly accurate artificial intelligence algorithm analyzes prostate biopsies and issues alerts when discrepancies with the pathologists’ initial diagnosis are identified. Alerts can include potential cancer missed and provide a safety net that helps minimize diagnostic errors in the lab by improving quality control. Galen Prostate has demonstrated outstanding results in clinical studies, including an unrivaled AUC (Area Under Curve) of 0.997 for cancer detection, and has already successfully detected missed cancers in real time.

“Medipath’s implementation of Galen Prostate represents an important milestone in our global expansion and extends the scope of cooperation between our companies to routine cancer diagnosis – the core of Medipath’s clinical practice,” said Joseph Mossel, CEO and co-founder of Ibex. “We are pleased to share the vision that AI-powered pathologists will take center stage in the future, with AI applications becoming the norm in the cancer journey and in patient care. ”

“This is a defining moment not only for Medipath, but also for pathology and cancer care in France, ”He told me Delphine Raoux, MD, Head of Innovation Technologies at Medipath. “Medipath is committed to exploring new technologies and providing the best service to its customers and ultimately their patients. This is an important step in leveraging our leadership position to support pathologists and help them improve diagnostic quality and workflow efficiency. AI can be a tool in the future of pathology, and we’re excited to be the premier lab France to reach this milestone. We look forward to working with Ibex on transformative solutions for cancer diagnosis. ”

About Ibex Medical Analytics

Ibex uses AI to develop clinical grade solutions that help pathologists detect and classify cancer in biopsies. Galen Prostate and Galen Breast are the very first AI-powered cancer diagnostic solutions used in routine clinical pathology and deployed in laboratories around the world, enabling pathologists to improve diagnostic accuracy, integrate a complete quality control and enable a more efficient workflow. Ibex solutions are based on deep learning algorithms trained by a team of pathologists, data scientists and software engineers. For more information, see

About Medipath

Medipath est From France the largest network of pathology laboratories, owned exclusively by 86 pathologists. Medipath fulfills a public health mission in the diagnosis of cancer. Its team has more than 350 employees, 5 pathologists who are experts in rare diseases and 6 molecular pathologists. It collaborates with more than 170 hospitals and clinics across France (including the American Hospital of Paris) and treats over 1,000,000 cases each year, including 70,000 cancer diagnoses. As a pioneer in the quality process (5 scopes of accreditation), Medipath participates in independent quality audits recognized at national level (AFAQAP) and worldwide (UK NEQAS, QCMD). In 2020, the group’s turnover will reach 60 million euros. For more information, see

Logo –

Logo –

Contact média Ibex Medical Analytics:

Julie Steigerwald

GK for Ibex

[email protected]

Contact média Medipath:

Mathilde Lise

Press relations agency for Medipath

[email protected]


Please enter your comment!
Please enter your name here